Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo fog targets stomach cancer spread in new trial

NCT ID NCT07517419

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a procedure called PIPAC, which turns chemotherapy drugs into a mist and sprays them directly into the abdomen. It is for people with stomach cancer that has spread to the lining of the belly. The goal is to see if this approach is safe and can help control the disease. About 30 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Feb 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients age \>= 18, \<= 80 years old 2. Performance status (WHO) \<=2 3. Histologically evidenced synchronous PM of gastric adenocarcinoma cancer 4. Peritoneal Cancer Index (PCI) score \> 8, or \<=8 and patient not fit for cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) 5. Patients with isolated ovarian metastasis could be included 6. White blood cells \>3.5000/mm3; neutrophils \> 1.500/mm3; platelets \>100,000/mm3 7. Creatinine \<1.5mg/dL and creatinine clearance \>60ml/min and serum total bilirubin \<2mg/dL 8. Ability to give written consent prior to commencement of treatment Exclusion Criteria: 1. Extraperitoneal metastases including liver metastases and malignant pleural effusion. The presence of suspicious retroperitoneal lymph nodes is not an exclusion criterium. 2. Patients with adenocarcinoma of Siewart I 3. Bowel obstruction, not tolerating oral diet 4. HER2+++ tumor with indicated for Trastuzumab therapy 5. Any laparotomy during 3 months before inclusion. (Laparoscopy is not an exclusion criterium) 6. Contraindicated to any drug contained in the chemotherapy regimen 7. Concomitant intraperitoneal chemotherapy, immunotherapy or target therapy 8. Active infectious (bacterial, viral) disease. Elevated CRP with no identified focus is not an exclusion criterium 9. Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma with peritoneal metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer peritoneal metastases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Chinese University of Hong Kong, Shatin, HK

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.